Vicore Pharma has carried out a primary issuance of shares of SEK 336 million at a subscription price of SEK 30 per share. The subscription price was determined through an accelerated book-building procedure.
Vicore Pharma is a rare disease pharmaceutical company focused on rare lung disorders and related indications. The company currently has two drug development programs, VP01, VP02 and VP03.
DNB Markets, Pareto Securities and Zonda Partners acted as joint global coordinators and joint bookrunners. Baker McKenzie acted as legal advisor to the banks. Joakim Falkner, Ian Gulam, Marlene Wiklund and Olof Larsson from Baker McKenzie's Capital Markets team in Stockholm were involved in the transaction.